Free Trial

Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis

+0.04 (+2.27%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
9,320 shs
Average Volume
208,077 shs
Market Capitalization
$5.15 million
P/E Ratio
Dividend Yield
Price Target

Processa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
344.4% Upside
$8.00 Price Target
Short Interest
24.82% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($3.90) to ($2.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

PCSA stock logo

About Processa Pharmaceuticals Stock (NASDAQ:PCSA)

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

PCSA Stock Price History

PCSA Stock News Headlines

Processa Pharmaceuticals Inc (PCSA)
See More Headlines
Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.11 per share


Free Float
Market Cap
$5.15 million
Not Optionable
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PCSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Processa Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCSA shares.
View PCSA analyst ratings
or view top-rated stocks.

What is Processa Pharmaceuticals' stock price target for 2024?

3 brokerages have issued 12-month target prices for Processa Pharmaceuticals' shares. Their PCSA share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 344.4% from the stock's current price.
View analysts price targets for PCSA
or view top-rated stocks among Wall Street analysts.

How have PCSA shares performed in 2024?

Processa Pharmaceuticals' stock was trading at $6.6920 at the beginning of the year. Since then, PCSA shares have decreased by 73.1% and is now trading at $1.80.
View the best growth stocks for 2024 here

When is Processa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our PCSA earnings forecast

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) posted its quarterly earnings results on Friday, May, 10th. The company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.07.

When did Processa Pharmaceuticals' stock split?

Processa Pharmaceuticals shares reverse split on the morning of Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCSA) was last updated on 5/25/2024 by Staff

From Our Partners